Fanconi anemia repair pathway dysfunction, a potential therapeutic target in lung cancer

Frontiers in Oncology

Volumn 4, Issue DEC, 2014, Pages

  Duan, Wenrui ^a   Gao, Li ^a   Aguila, Brittany ^a   Kalvala, Arjun ^a   Otterson, Gregory A ^a   Villalona Calero, Miguel A ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Fanconi anemia; Fatsi; Lung cancer; Pathway dysfunction; Therapeutic target

Indexed keywords

ANTINEOPLASTIC AGENT; ARRY 575; CHECKPOINT KINASE 1; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FANCONI ANEMIA GROUP D2 PROTEIN; NAVITOCLAX; PROTEIN BCL 2; PROTEIN BCL XL; TALAZOPARIB; UNCLASSIFIED DRUG; VELIPARIB;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DNA REPAIR; FANCONI ANEMIA; GENE SILENCING; HISTOLOGY; HUMAN; HUMAN TISSUE; IC50; IMMUNOFLUORESCENCE; LUNG CANCER; MTT ASSAY; NON SMALL CELL LUNG CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SMALL CELL LUNG CANCER; WESTERN BLOTTING;

EID: 84922548577     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00368     Document Type: Article

References (40)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin (2013) 63(1):11-30. doi: 10.3322/caac.21166
2. Friboulet L, Olaussen KA, Pignon JP, Shepherd FA, Tsao MS, Graziano S, et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med (2013) 368(12):1101-10. doi:10.1056/NEJMoa1214271
3. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med (2006) 355(10):983-91. doi:10.1056/NEJMoa060570
4. Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med (2003) 9:568-74. doi:10.1038/nm852
5. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature (2005) 434(7035):913-7. doi:10.1038/nature03443
6. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 361(2):123-34. doi:10.1056/NEJMoa0900212
7. Lyakhovich A, Surralles J. Disruption of the Fanconi anemia/BRCA pathway in sporadic cancer. Cancer Lett (2006) 232:99-106. doi:10.1016/j.canlet.2005.07.038
8. Neveling K, Kalb R, Florl AR, Herterich S, Friedl R, Hoehn H, et al. Disruption of the FA/BRCA pathway in bladder cancer. Cytogenet Genome Res (2007) 118:166-76. doi:10.1159/000108297
9. Tischkowitz M, Xia B, Sabbaghian N, Reis-Filho JS, Hamel N, Li G, et al. Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci U S A (2007) 104:6788-93. doi:10.1073/pnas.0701724104
10. D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer (2003) 3(1):23-34. doi:10.1038/nrc970
11. Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell (2006) 22(6):719-29. doi:10.1016/j.molcel.2006.05.022
12. Smogorzewska A, Matsuoka S, Vinciguerra P, McDonald ER III, Hurov KE, Luo J, et al. Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell (2007) 129:289-301. doi:10.1016/j.cell.2007.03.009
13. Taniguchi T, D'Andrea AD. Molecular pathogenesis of Fanconi anemia: recent progress. Blood (2006) 107(11):4223-33. doi:10.1182/blood-2005-10-4240
14. Vaz F, Hanenberg H, Schuster B, Barker K, Wiek C, Erven V, et al. Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet (2010) 42:406-9. doi:10.1038/ng.570
15. Somyajit K, Subramanya S, Nagaraju G. RAD51C: a novel cancer susceptibility gene is linked to Fanconi anemia and breast cancer. Carcinogenesis (2010) 31:2031-8. doi:10.1093/carcin/bgq210
16. Kim Y, Lach FP, Desetty R, Hanenberg H, Auerbach AD, Smogorzewska A. Mutations of the SLX4 gene in Fanconi anemia. Nat Genet (2011) 43:142-6. doi:10.1038/ng.750
17. Stoepker C, Hain K, Schuster B, Hilhorst-Hofstee Y, Rooimans MA, Steltenpool J, et al. SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. Nat Genet (2011) 43:138-41. doi:10.1038/ng.751
18. Bogliolo M, Schuster B, Stoepker C, Derkunt B, Su Y, Raams A, et al. Mutations in ERCC4, encoding the DNA-repair endonuclease XPF, cause Fanconi anemia. Am J Hum Genet (2013) 92(5):800-6. doi:10.1016/j.ajhg.2013.04.002
19. Howlett NG, Harney JA, Rego MA, Kolling FW IV, Glover TW. Functional interaction between the Fanconi Anemia D2 protein and proliferating cell nuclear antigen (PCNA) via a conserved putative PCNA interaction motif. J Biol Chem (2009) 284(42):28935-42. doi:10.1074/jbc.M109.016352
20. Duan W, Gao L, Zhao W, Leon M, Sadee W, Webb A, et al. Assessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents. Transl Res (2013) 161(3):156-64. doi:10.1016/j.trsl.2012.09.003
21. Duan W, Gao L, Wu X, Wang L, Nana-Sinkam SP, Otterson GA, et al. MicroRNA-34a is an important component of PRIMA-1-induced apoptotic network in human lung cancer cells. Int J Cancer (2010) 172:313-20. doi:10.1002/ijc.25049
22. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res (2012) 72(21):5588-99. doi:10.1158/0008-5472.CAN-12-2753
23. Murai J, Huang SY, Renaud A, Zhang Y, Ji J, Takeda S, et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther (2014) 13(2):433-43. doi:10.1158/1535-7163.MCT-13-0803
24. Chen CC, Kennedy RD, Sidi S, Look AT, D'Andrea A. CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors. Mol Cancer (2009) 8:24. doi:10.1186/1476-4598-8-24
25. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell (2003) 3:421-9. doi:10.1016/S1535-6108(03)00110-7
26. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res (2008) 68(9):3421-8. doi:10.1158/0008-5472.CAN-07-5836
27. Shoemaker AR, Mitten MJ, Adickes J, Ackler S, Refici M, Ferguson D, et al. Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res (2008) 14(11):3268-77. doi:10.1158/1078-0432.CCR-07-4622
28. Rudin CM, Hann CL, Garon EB, Ribeiro deOliveiraM, Bonomi PD, Camidge DR, et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res (2012) 18(11):3163-9. doi:10.1158/1078-0432.CCR-11-3090
29. Evers B, Helleday T, Jonkers J. Targeting homologous recombination repair defects in cancer. Trends Pharmacol Sci (2010) 31(8):372-80. doi:10.1016/j.tips.2010.06.001
30. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer (2008) 8(3):193-204. doi:10.1038/nrc2342
31. Tischler J, Lehner B, Frazer AG. Evolutionary plasticity of genetic interaction networks. Nat Genet (2008) 40:390-1. doi:10.1038/ng.114
32. Luo J, Somilini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell (2009) 136:823-37. doi:10.1016/j.cell.2009.02.024
33. Narayan G, Arias-Pulido H, Nandula SV, Basso K, Sugirtharaj DD, Vargas H, et al. Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res (2004) 64(9):2994-7. doi:10.1158/0008-5472.CAN-04-0245
34. Wang Z, Li M, Lu S, Zhang Y, Wang H. Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway. Cancer Biol Ther (2006) 5(3):256-60. doi:10.4161/cbt.5.3.2380
35. Wei M, Xu J, Dignam J, Nanda R, Sveen L, Fackenthal J, et al. Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers. Breast Cancer Res Treat (2008) 111(1):113-20. doi:10.1007/s10549-007-9766-6
36. Potapova A, Hoffman AM, Godwin AK, Al-Saleem T, Cairns P. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer. Cancer Res (2008) 68(4):998-1002. doi:10.1158/0008-5472.CAN-07-2418
37. Hess CJ, Ameziane N, Schuurhuis GJ, Errami A, Denkers F, Kaspers GJ, et al. Hypermethylation of the FANCC and FANCL promoter regions in sporadic acute leukaemia. Cell Oncol (2008) 30(4):299-306. doi:10.3233/CLO-2008-0426
38. Dhillon VS, Shahid M, Husain SA. CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin. Mol Cancer (2004) 3:33. doi:10.1186/1476-4598-3-33
39. Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res (2008) 68(8):2581-6. doi:10.1158/0008-5472.CAN-08-0088
40. Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H, et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol (2010) 17(6):688-95. doi:10.1038/nsmb.1831